Race, Pharmacogenomics, and Marketing: Putting BiDil in Context

American Journal of Bioethics 6 (5):W1-W5 (2006)
This article endeavors to place into context recent developments surrounding the United States Food and Drug Administration recent approval of BiDil? (isosorbide dinitrate/hydralazine hydrochloride) (NitroMed, Inc., Lexington, MA) as the first ever race-specific drug?in this case to treat heart failure in African Americans. It focuses in particular on both commercial incentives and statistical manipulation of medical data as framing the drive to bring BiDil to market as a race-specific drug. In current discourse about pharmacogenomics, targeting a racial audience is perceived as necessary because at this point the technology and resources do not exist to scan efficiently every individual's genetic profile. The article argues that medical researchers may say they are using race as a surrogate to target biology in drug development, but corporations are using biology as a surrogate to target race in drug marketing. Pharmacogenomics may hold great promise, but on our way to that Promised Land, it is imperative to review such short cuts with a critical eye
Keywords No keywords specified (fix it)
Categories (categorize this paper)
DOI 10.1080/15265160600755789
 Save to my reading list
Follow the author(s)
My bibliography
Export citation
Find it on Scholar
Edit this record
Mark as duplicate
Revision history
Request removal from index
Download options
Our Archive

Upload a copy of this paper     Check publisher's policy     Papers currently archived: 26,769
External links

Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
Through your library
References found in this work BETA

Add more references

Citations of this work BETA

No citations found.

Add more citations

Similar books and articles
The Troubling Persistence of Race in Pharmacogenomics.Jonathan Kahn - 2012 - Journal of Law, Medicine & Ethics 40 (4):873-885.
“Special Treatment”: BiDil, Tuskegee, and the Logic of Race.Susan M. Reverby - 2008 - Journal of Law, Medicine & Ethics 36 (3):478-484.
Popular Representations of Race: The News Coverage of BiDil.Timothy Caulfield & Simrat Harry - 2008 - Journal of Law, Medicine & Ethics 36 (3):485-490.
Pharmacogenomics, Ethics, and Public Policy.Karen Peterson-Iyer - 2008 - Kennedy Institute of Ethics Journal 18 (1):pp. 35-56.
The Likelihood of Deception in Marketing.Homer B. Warren, David J. Burns & James Tackett - 2012 - Business and Professional Ethics Journal 31 (1):109-134.
Epistemological Structures in Marketing.Donald P. Robin - 1991 - Business Ethics Quarterly 1 (2):185-200.

Monthly downloads

Added to index


Total downloads

13 ( #350,328 of 2,158,887 )

Recent downloads (6 months)

1 ( #353,783 of 2,158,887 )

How can I increase my downloads?

My notes
Sign in to use this feature

There  are no threads in this forum
Nothing in this forum yet.

Other forums